X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Pursuant to this acquisition, NightHawk announced it plans to migrate manufacturing of ANTHIM® to its planned Scorpion biomanufacturing facility in Manhattan, Kansas, which is being constructed to support development of commercial-scale biologics and large molecules.
Lead Product(s): Obiltoxaximab
Therapeutic Area: Infections and Infectious Diseases Product Name: Anthim
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Elusys Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 20, 2022
Details:
New 3-D process designed to increase yield and improve operating efficiency for rapid and scalable manufacturing of HS-110, gp-96 based cell therapies and other cellular products.
Lead Product(s): Viagenpumatucel-L,Erlotinib
Therapeutic Area: Oncology Product Name: HS-110
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2022
Details:
The strategic acquisition of Elusys is intended to enhance Heat’s immunotherapy portfolio and further position Heat to take a lead role in the biodefense space. The addition of ANTHIM (obiltoxaximab) Injection, together with Heat’s previously announced RapidVax® platform.
Lead Product(s): Obiltoxaximab
Therapeutic Area: Infections and Infectious Diseases Product Name: Anthim
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Elusys Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 21, 2021
Details:
The patent covers compositions of matter that are part of Heat's gp96 platform (antigen presentation, T cell activation, TLR activation) in combination with Inducible T cell Co-stimulator (ICOS) ligand or ICOSL, a T cell immune booster, in a single therapy.
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2020
Details:
Heat Biologics been issued a patent (US Patent No. 10,758,611) by the U.S. Patent and Trademark Office (USPTO) covering compositions of matter that are part of Heat's gp96 platform in combination with a T cell costimulatory agonist in a single therapy.
Lead Product(s): Viagenpumatucel-L,HS-130,Undisclosed
Therapeutic Area: Oncology Product Name: HS-110
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2020
Details:
Heat's COVID-19 vaccine is designed to drive T cell immunity, while also activating antibody responses and innate immunity, which may complement conventional COVID-19 vaccines in combination approaches by enhancing T cell immunity.
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2020
Details:
First patient has been treated in the Company's first-in-human Phase 1 clinical trial evaluating PTX-35, the first antibody product candidate developed by Heat Biologics' Pelican Therapeutics subsidiary.
Lead Product(s): PTX-35
Therapeutic Area: Oncology Product Name: PTX-35
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
Preclinical studies have demonstrated PTX-35, in combination with antigen-driven immunotherapies, resulted in enhanced anti-tumor properties, including potent proliferation of antigen-specific T cells, production of effector cytokines and augmented effector immune function.
Lead Product(s): PTX-35
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2020
Details:
Median overall survival (OS) of 28.7 months for HS-110 in combination with nivolumab in previously treated checkpoint inhibitor naïve non-small cell lung cancer (NSCLC) patients.
Lead Product(s): Viagenpumatucel-L,Nivolumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
Details:
Heat Biologics continue to make good progress on its clinical-stage portfolio, as well as its COVID-19 vaccine platform, and look forward to presenting additional HS-110 data on May 29 at ASCO.
Lead Product(s): Viagenpumatucel-L,Nivolumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
